AXDX earnings

TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.

TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year.Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in

TUCSON, Ariz., Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2024. "During the fourth quarter, we continued our momentum across our innovation pipeline with significant progress of the clinical trial for our Accelerate WAVE™ system and the Gram-Negative assay while also

TUCSON, Ariz., Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the third quarter ended September 30, 2024. "We are excited by the momentum we're building across our innovation pipeline, underscored by the successful launch of the clinical trial for our WAVETM system and the Gram-Negative assay.  This quarter also marked a significant milestone with FDA clearance of our Accelerate ArcTM system, a testament to our commitment to breakthrough solutions in diagnostics," commented Jack Phillips, President and CEO of Accel

TUCSON, Ariz., Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m. Eastern Time to review 2024 third quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 1269422. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call will

TUCSON, Ariz., Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the second quarter ended June 30, 2024. "During the quarter we completed our pre-clinical trial demonstrating strong analytical performance of our WAVETM System and Gram-Negative Positive Blood Culture (PBC) assay. We are pleased to announce our pre-clinical trial was a success," commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc. "Additionally, we were able to raise an additional $15 million with certain existing noteholders, whic

TUCSON, Ariz., Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced that management will host a conference call today, Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to review 2024 second quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 9884567. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call

TUCSON, Ariz., May 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024. "During the quarter we installed our first pre-clinical trial site demonstrating our ability to successfully ship, install, train and run the Accelerate Wave™ system with Gram-Negative Positive Blood Culture samples in a clinical microbiology lab," commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc.  "We continue to target starting our clinical trial towards the end of the second q

TUCSON, Ariz., May 2, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to review 2024 first quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 2853328. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call wi

TUCSON, Ariz., March 28, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023. "In 2023, we made significant progress with the development of our next-generation rapid Antibiotic Susceptibility Testing system, Accelerate Wave™. We continue to advance this important development program and believe that we remain on plan to begin our clinical trials in the second quarter of 2024," commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc.  "In addition, we continu

TUCSON, Ariz., March 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m. Eastern Time to review 2023 fourth quarter and full year results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 7172610. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A re

TUCSON, Ariz., Jan. 7, 2024 /PRNewswire/ --  Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2023. "In 2023, we made significant progress with the development of our next-generation rapid Antimicrobial Susceptibility Testing system, Accelerate WaveTM. We continue to advance this important development p

TUCSON, Ariz., Aug. 10, 2023 /PRNewswire/ --  Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the second quarter for the period ended June 30, 2023. "Throughout the quarter, we've significantly advanced our Wave Program," stated Jack Phillips, CEO of Accelerate Diagnostics, Inc.  "Our recent achievements underscore our commitment to delivering a Wave pre-clinical positive blood culture study by year-end.  Moreover, we're pleased with the ongoing progress of our BD partnership, resulting in the strongest quarter for US contracted instruments sin

TUCSON, Ariz., July 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Thursday, August 10, 2023, at 4:30 p.m. Eastern Time to review 2023 second quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 4614555. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the c

TUCSON, Ariz., May 11, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the first quarter for the period ended March 31, 2023. "Our first quarter results are in line with expectations, and I am optimistic about the remainder of 2023 and beyond," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc. "We are encouraged by our partnership with Becton Dickinson, which is gaining momentum, solidifying market share, and opening avenues for innovation and growth. I am particularly excited about the incred

TUCSON, Ariz., April 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Thursday, May 11, 2023, at 4:30 p.m. Eastern Time to review 2023 first quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 1816344. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call

TUCSON, Ariz., March 29, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022. "In 2022, we achieved another year of revenue growth thanks to our base book of satisfied customers," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc., "Though we fell short of our guidance target, we're emboldened by our new partnership with Becton Dickinson and the significant product development milestones we've achieved. The Accelerate Team is fully committed to dr

TUCSON, Ariz., March 15, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Wednesday, March 29, 2023, at 4:30 p.m. Eastern Time to review 2022 fourth quarter and full year results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 6648486. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A

TUCSON, Ariz., Nov. 14, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the third quarter for the period ended September 30, 2022. "Our third quarter results were generally in line with my expectations," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc.  "While I was pleased with the significant progress we made in readying for commercialization with BD and on development of our next generation AST platform, the FDA's challenge of Arc's regulatory status was an unexpected set-back. Despite thi

TUCSON, Ariz., Oct. 24, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Monday, November 14, 2022, at 4:30 p.m. Eastern Time to review 2022 third quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 5844198. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the ca

TUCSON, Ariz., Aug. 15, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the second quarter for the period ended June 30, 2022. "In addition to a solid quarter, I am pleased to announce that we will be joining forces with Becton Dickinson to commercialize our products globally," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc.  "Our global commercial partnership with BD comes at a time when the hospital selling environment is improving, we are firing on all cylinders in R&D and are taking mean

TUCSON, Ariz., July 25, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Monday, August 15, 2022, at 4:30 p.m. Eastern Time to review 2022 second quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until November 15, 2022. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 8181593. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A repla

TUCSON, Ariz., May 16, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the first quarter for the period ended March 31, 2022. "First quarter financial results were consistent with our expectations," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc.  "We also launched new products, progressed key R&D milestones, and improved our balance sheet position during the quarter." First Quarter 2022 Highlights Added 2 contracted instruments and brought 5 instruments live in the U.S. in the quarter.Added

TUCSON , April 29, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Monday, May 16, 2022, at 4:30 p.m. Eastern Time to review 2022 first quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until August 15, 2022. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 0355137. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the ca

TUCSON, Ariz., March 8, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2021. Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc., commented, "The addition of new contracts, clinically live customers, and new prospects to our sales funnel, made the fourth quarter our most commercially productive quarter of the year.  Strong R&D execution in 2021 has enabled the sale and early marketing of our expanded product portfolio.  The new PhenoAST Test Kit is bei

TUCSON, Ariz., Feb. 24, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Wednesday, March 8, 2022, at 4:30 p.m. Eastern Time to review 2021 fourth quarter and full year financial results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until June 7, 2022. To listen by phone, dial +1.877.883.0383 and enter the conference ID: 8732862. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the con

TUCSON, Ariz., Nov. 9, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced preliminary financial results for the third quarter for the period ended September 30, 2021, which remain subject to quarter end closing adjustments. "The resurgence of COVID hospitalizations impacted our commercial execution in the quarter," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc.  "Despite this recurring impediment to closing new accounts, I am pleased our team continued to build our funnel of prospective customers, and advance our d

TUCSON, Ariz., Oct. 19, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, November 9, 2021, at 4:30 p.m. Eastern Time to review 2021 third quarter financial results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until February 9, 2022. To listen by phone, dial +1.877.883.0383 and enter the conference ID: 7399350.  International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of th

TUCSON, Ariz., Aug. 5, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the second quarter for the period ended June 30, 2021. "Second quarter and year to date financial results were consistent with our expectations," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc. "We also launched our AST focused test kit, concluded our multi-hospital registry study with compelling new data, and advanced other key commercial and product development priorities during the quarter." Second Quarter 2021 Highlig